Supplementary Figure 4 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Type and frequency of MET TKD mutations across cancer types in cohort #1. (A) Frequency of MET TKD mutations in various cancer types in cohort #1 according to OncoKB status; the numbers above each bar indicate the number of cases with MET TKD mutations (regardless OncoKB annotations) out of the total of cases of each cancer type. (B) Detailed oncogenic / likely oncogenic MET TKD mutations according to cancer type in cohort #1.